MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in the April 22 issue of the

2025年4月28日星期一——根据4月22日在线发表于《美国医学会杂志》上的一项研究，对于心肌梗死（MI）患者，早期口服联合降脂治疗（LLT）是有益的。

Journal of the American College of Cardiology

美国心脏病学会杂志

.

。

Margret Leosdottir, M.D., Ph.D., from Skåne University Hospital in Malmö, Sweden, and colleagues examined the impact of delayed treatment escalation on outcomes by comparing early versus late oral combination LLT in LLT-naïve patients hospitalized for MI and discharged on statins. Differences in the risks for major adverse cardiovascular events (MACE; death, MI, stroke), MACE components, and cardiovascular death were compared between patients with ezetimibe added to statins ≤12 weeks after discharge (early combination therapy), from 13 weeks to 16 months (late combination therapy), or not at all..

玛格丽特·莱奥斯多蒂尔（Margret Leosdottir），医学博士、哲学博士，来自瑞典马尔默的斯科讷大学医院，她和同事们通过比较早期与晚期口服联合LLT治疗，研究了延迟治疗升级对结果的影响，研究对象为因心肌梗死（MI）住院且出院后仅使用他汀类药物的LLT初治患者。研究人员比较了在出院后12周内（早期联合治疗）、13周至16个月（晚期联合治疗）或完全未添加依折麦布的患者，在主要不良心血管事件（MACE；包括死亡、心肌梗死、中风）、MACE各组成部分以及心血管死亡风险方面的差异。

The study included 35,826 patients. In all groups, high-intensity statin use was ≥98 percent. The researchers found that 2,570 patients had MACE during a median 3.96 years. One-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe, respectively. For late versus early combination therapy, weighted risk differences in MACE were 0.6, 1.1, and 0.7 percent at one, two, and three years, respectively; the three-year hazard ratio was 1.14 (95 percent confidence interval, 0.95 to 1.41).

该研究纳入了35,826名患者。在所有组中，高强度他汀类药物的使用率均≥98%。研究人员发现，在中位随访3.96年期间，有2,570名患者发生了主要不良心血管事件（MACE）。依折麦布早期、晚期和未使用的患者，一年内每100患者年的MACE发生率分别为1.79、2.58和4.03。对于晚期与早期联合治疗，MACE的加权风险差异在一年、两年和三年时分别为0.6%、1.1%和0.7%；三年的风险比为1.14（95%置信区间，0.95至1.41）。

Risk differences were 0.7, 1.6, and 1.9 percent at one, two, and three years for those receiving no ezetimibe; the three-year hazard ratio was 1.29 (95 percent confidence interval, 1.12 to 1.55)..

三年风险差异分别为0.7%、1.6%和1.9%，三年危险比为1.29（95%置信区间，1.12至1.55）。

'The need for combination therapy is inevitable for most patients after an MI,' the authors write. 'A delayed approach to LLT escalation is associated with avoidable harms.'

“大多数心肌梗死患者不可避免地需要联合治疗，”作者写道。“延迟升高LLT与可避免的危害相关。”

Several authors disclosed ties to the biopharmaceutical industry.

若干作者披露了与生物制药行业的联系。

Abstract/Full Text

摘要/全文

Editorial (subscription or payment may be required)

社论（可能需要订阅或付费）

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最佳资讯到您的邮箱。